The word we are discussing here is
Biosimilars. Which are 'generic' biological drugs. Freeing up the IP would create a big biosimilar market. A lot of countries such as India, Gulf states, Brazil, Turkey, South Africa are getting big into biosimilars.
There are some issues with skills. If you look at countries who do a lot of pharmaceutical work, you tend to find the companies are quite bunched together. Ireland is a great example with LOADS of companies based around Dublin and Cork. Ireland invested heavily some years back to grow a pharmaceutical industry through targeted education and big tax breaks. There is now a critical mass of educated people in Ireland who tend to flit from company to company and Ireland is an attractive country to set up shop now.
Countries need to grow that skills base or buy it in. India is growing it, the gulf states are buying it in.
One big reason why companies won't release their IP for these vaccines is that the technology can be very useful once known. Once you know how to modify and produce an adenovirus or mRNA vaccine for one disease, it takes no time to make a different vaccine. This is how the AZ and Pfizer vaccines came out so quick. Knowing how to make a vaccine quickly is great but you wouldn't want to spread that around too much.